

1 Supplemental Materials

2 List of Supplemental Tables:

13 **Supplemental Table 1: Summary of results of *in vitro* combination studies in the AML12-HBV10 cell culture system with**
 14 **rcDNA quantitation using bDNA assay**

Inhibitor A	Inhibitor B	Inhibitor A EC ₅₀ (µM)	Inhibitor B EC ₅₀ (µM or µg/mL)	Synergy Volume (µM ² %)*	Synergy Log Volume	Antagonism Volume (µM ² %)*	Antagonism Log Volume	Conclusion
AB-423	ETV	0.231	0.012	0	0	-1.29	-0.19	Additive
AB-423	ARB- 1740**	0.250	0.032	2.14	0.31	0	0	Additive
AB-423	ARB- 1467**	0.291	0.030	6.96	1	-0.81	-0.12	Additive

15 *At 99.9% confidence interval; ** µg/mL. Shown are the mean values of quadruplicate samples.

16 **Supplemental Table 2: Summary of results of *in vitro* combination studies in the HepDE19 cell culture system with rcDNA**
17 **quantitation using bDNA assay**

Inhibitor A	Inhibitor B	Inhibitor A EC ₅₀ (μM)	Inhibitor B EC ₅₀ (μg/mL)	Synergy Volume (μM ² %)*	Synergy Log Volume	Antagonism Volume (μM ² %)*	Antagonism Log Volume	Conclusion
AB-423	TDF	0.454	0.088	12.07	1.73	0	0	Additive

18 *At 99.9% confidence interval. Shown are the mean values of quadruplicate samples

19 **Supplemental Table 3: Summary of results of *in vitro* combination studies in the HepBHAe82 cell culture system (precore
20 RNA expression/qRT-PCR assay)**

Inhibitor A	Inhibitor B	Inhibitor A EC ₅₀ (μM)	Inhibitor B EC ₅₀ (nM or μg/mL)	Synergy Volume (μM ² %)*	Synergy Log Volume	Antagonism Volume (μM ² %)*	Antagonism Log Volume	Conclusion
AB-423	ETV	0.658	0.300	679.15	169.79	0	0	Synergistic
AB-423	ARB-1740**	0.087	0.006	123.96	30.95	-0.26	-0.06	Synergistic

21 *at 99.9% confidence interval; ** μg/mL. Shown are the mean values of quadruplicate samples

22

Supplemental Table 4: Summary of results of *in vitro* combination studies in HBV infected PHH (HBV DNA/qPCR assay)

Inhibitor A	Inhibitor B	Inhibitor A EC ₅₀ (µM) (HBV DNA)	Inhibitor B EC ₅₀ (nM or IU/mL) (HBV DNA) [#]	Synergy Volume (µM ² %) [*]	Synergy Log Volume	Antagonism Volume (µM ² %) [*]	Antagonism Log Volume	Conclusion
AB-423	Interferon- α2a	0.92 µM	0.62, 2.15 IU/mL	78.7	17.9	-11.2	2.5	Moderate Synergy
AB-423	TAF	0.88 µM	0.56, 0.41 nM	56.0	12.7	-8.4	1.9	Moderate Synergy

23

*at 95% confidence interval; ** µg/mL; #duplicate experimental results

24

Supplemental Table 5: Summary of results of *in vitro* combination studies in HBV infected PHH (HBsAg ELISA assay)

Inhibitor A	Inhibitor B	Inhibitor A EC ₅₀ (µM) (HBsAg)	Inhibitor B EC ₅₀ (nM or IU/mL) (HBsAg) [#]	Synergy Volume (µM ² %) [*]	Synergy Log Volume	Antagonism Volume (µM ² %) [*]	Antagonism Log Volume	Conclusion
AB-423	Interferon- α2a	4.08 µM	13.2, 13.8 IU/mL	63.1	14.4	0	0	Moderate Synergy
AB-423	TAF	7.8 µM	>100, >100 nM	117.1	26.7	-0.24	0.1	Strong Synergy

25

*at 95% confidence interval; [#] duplicate experimental results

26 **Supplemental Table 6: Summary of results of *in vitro* combination studies in HBV infected PHH (HBeAg ELISA assay)**

Inhibitor A	Inhibitor B	Inhibitor A EC ₅₀ (µM) (HBeAg)	Inhibitor B EC ₅₀ (nM or IU/mL) (HBeAg) [#]	Synergy Volume (µM ² %) [*]	Synergy Log Volume	Antagonism Volume (µM ² %) [*]	Antagonism Log Volume	Conclusion
AB-423	Interferon- α2a	4.27 µM	12.66, 10.24 IU/mL	155.1	35.3	0	0	Strong Synergy
AB-423	TAF	8.58 µM	>100, >100 nM	17.9	4.1	0	0	Additive

27 *at 95% confidence interval; [#] duplicate experimental results